GDRX - Goodrx Holdings Inc

GDRX - Goodrx Holdings Inc

https://www.goodrx.com

Recent News

Powered by Alpha Vantage

Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk - Novo Nordisk ( NYSE:NVO )

Benzinga • 3 weeks, 5 days ago • score: 0.32

The FLOW trial showed a 24% lower risk of kidney disease progression and deaths with Ozempic. Over 3,500 patients in 28 countries participated; trial stopped early due to strong efficacy. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.

GoodRx ( GDRX ) Stock Is Sliding Tuesday: What's Going On? - GoodRx Holdings ( NASDAQ:GDRX )

Benzinga • 3 weeks, 6 days ago • score: 0.17

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access - GoodRx Holdings ( NASDAQ:GDRX ) , Eli Lilly ( NYSE:LLY )

Benzinga • 3 weeks, 6 days ago • score: 0.19

GoodRx Holdings Inc. GDRX shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S NVO to offer discounted GLP-1 medications at fixed pricing nationwide. Check out the current price of GDRX stock here.

Why Is GoodRx Stock Skyrocketing Monday? - GoodRx Holdings ( NASDAQ:GDRX )

Benzinga • 4 weeks ago • score: 0.23

Eligible patients can access Ozempic and Wegovy pens for $499/month via GoodRx. Over the past year, nearly 17 million people sought GLP-1 info on GoodRx, up 22%. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

GoodRx Holdings, Inc. provides information and tools that allow consumers to compare prices and save when buying prescription drugs in the United States. The company is headquartered in Santa Monica, California.

52W High

$7.90

52W Low

$3.31

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.24

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

44.44

Forward P/E (<15 better)

9.15

EV/EBITDA (<8 favorable)

9.30

EV/Revenue (<3 favorable)

2.07

P/S (TTM) (<3 favorable)

1.74

P/B (<3 favorable)

2.16

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

12.67%

Institutions (25–75% balanced)

62.80%

Shares Outstanding

98,581,000

Float

86,435,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

799,874,000

Gross Profit (TTM)

749,283,000

EPS (TTM)

0.09

Profit Margin (>10% good)

0.04%

Operating Margin (TTM) (higher better)

0.13%

ROE (TTM) (>15% strong)

0.05%

EPS YoY (Quarterly) (>10% good)

1.02

Revenue YoY (Quarterly) (>8% good)

0.01

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—